Sort   by:  
 Page size 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065760 | Pride
Targeted protein degradation Central nervous system Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Mus musculus (Mouse) 
2025-10-13 | PXD065731 | Pride
Targeted protein degradation Central nervous system Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Mus musculus (Mouse) 
2025-10-13 | PXD065740 | Pride
Targeted protein degradation Central nervous system Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065722 | Pride
Central nervous system Targeted protein degradation Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065750 | Pride
Targeted protein degradation Central nervous system Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065724 | Pride
Targeted protein degradation Central nervous system Glycogen synthase kinase 3 Direct-to-biology 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065662 | Pride
Central nervous system Targeted protein degradation Direct-to-biology Glycogen synthase kinase 3 
ProteomicsDiscovery of a CNS active GSK3 degrader using orthogonally reactive linker screening
Bifunctional targeted protein degraders, also known as Proteolysis Targeting Chimeras (PROTACs), are an emerging drug modality that may offer a new approach to understand and treat neurodegenerative diseases. These molecules have a non-occupancy based, sub-stoichiometric mechanism of action which re...
ORGANISM(S): Homo sapiens (Human) 
2025-10-13 | PXD065692 | Pride
Central nervous system Targeted protein degradation Glycogen synthase kinase 3 
Sort   by:  
 Page size